Welcome to PathPulse: Pathology Innovators in Action, your go-to podcast for practical and implemented digital pathology insights and solutions. This podcast is sponsored by the Digital Diagnostic Summit and Lumea.
Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part of Owkin’s ongoing collaboration with Gustave Roussy and The Centre Léon Bérard through PortrAIt, a French consortium to accelerate precision medicine through AI-enabled digital pathology, this tool aims to significantly accelerate and expand access to gBRCA testing that too many patients may not be considered for.
Deciphex today announced its participation in VICT3R, a pioneering initiative focused on transforming nonclinical drug and chemical safety evaluation. VICT3R is a public-private partnership supported by the Innovative Health Initiative Joint Undertaking (IHI JU), with the goal of significantly reducing the use of animals in experimental studies. The initiative aims to replace animals in concurrent control groups (CCGs) with Virtual Control Groups (VCGs), leveraging advanced statistical and artificial intelligence (AI) techniques.
PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced a partnership with the Crohn’s & Colitis Foundation. The collaboration will empower academic and biopharmaceutical researchers to unlock insights into inflammatory bowel disease (IBD) through the unique combination of quantitative histopathology data and well-characterized multi-modal clinical and molecular data.
Rick Salmon, CEO of PathQA, will be presenting at the International Image Conference (IIC) in London on October 8, 2024, at 9:40 AM. His talk, titled "A Pathology of Digitisation in Digital Pathology - Scanner Colour QA," will delve into the significance of accurate color reproduction in digital pathology and its implications for diagnostics and research.
In a new study, researchers at the National Taiwan University Hospital and JelloX Biotech Inc. developed a novel computer-assisted tool for three-dimensional (3D) imaging of PD-L1 expression in immunofluorescence-stained and optically cleared breast cancer specimens. The proposed 3D framework showed high overall agreement with traditional, clinical-grade two-dimensional (2D) staining techniques in terms of morphological characteristics and PD-L1 expression assessment.
Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, today announced the launch of Concentriq® Embeddings and the Proscia AI Toolkit, enabling life sciences organizations to accelerate the discovery and development of novel therapies and diagnostics. Integrated into Proscia’s Concentriq platform, Concentriq Embeddings seamlessly delivers a collection of pathology foundation models to AI developers and research scientists, allowing them to leverage their organization’s large proprietary datasets and execute models in routine workflows.
HistoWiz, a leader in digital pathology services, announces the addition of GLP-compliant lab services including routine histology (H&E, trichrome, etc.) and immunohistochemistry (IHC). The addition of GLP leverages HistoWiz’s deep expertise in pre-clinical research pathology processes from wet tissue to slide digitization. Pathology consultation for GLP studies is also available.
A uterine section showed thickening with cystic cavities and hyperplastic endometrial glands. Microscopically, endometrial glands were found within the myometrium, some lined by keratinized epithelium. The diagnosis is uterine adenomyosis and cystic endometrial hyperplasia.
Mindpeak, the leader in AI-powered pathological solutions, today announced it has raised $15.3 million in a Series A funding round. The round was led by ZEISS Ventures and InnoVentureFund with participation from - amongst others - AI.FUND and the European Innovation Council Fund. While Mindpeak has a cash-flow positive core business, this new investment will enable the company to further expand the commercialisation of its pioneering technologies across several geographies.
